Rapid Nutrition

Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.

Plug & Play is turning its attention to nutrition products designed to accompany GLP-1 weight-loss medications, viewing the microbiome field as the next growth area. The idea is to support people taking drugs like Ozempic with foods or supplements that address side effects and nutritional gaps while on treatment. The move signals growing investment interest in products tailored to the rapidly expanding GLP-1 user base.

The UK Advertising Standards Authority has highlighted breaches of health-claim rules as more food brands market products with functional health benefits. The regulator's intervention signals growing scrutiny of nutrition and wellness marketing, as companies increasingly promote added vitamins, probiotics and other functional ingredients in everyday foods.

Supplement brand Smidge has introduced a nutrition bundle combining five supplements into a single daily routine, aimed at people taking GLP-1 weight-loss medications. The concept targets nutritional gaps reported by users of drugs like Ozempic and Wegovy, who often eat less and may miss key nutrients. It reflects a broader wave of products being marketed to the fast-growing GLP-1 user base.

A new report finds that 12.4% of teenagers taking GLP-1 weight-loss and diabetes medications are diagnosed with vitamin D deficiency within a year, and few of them receive nutrition counseling to offset the risk. The findings raise concerns about whether young patients on these increasingly prescribed drugs are getting adequate dietary support alongside treatment.